Introduction
Lung cancer is the leading cause of cancer death in the United States in both men and women (1) . Approximately 15% of all lung cancers are of small cell histology, characterized by exceptionally rapid proliferation and early dissemination to metastatic sites. Although standard of care platinum-based chemotherapy induces responses in up to 80% of newly diagnosed SCLC cases, these responses are of short duration and the median survival in patients with advanced SCLC is less than one year from the time of diagnosis (2) . New therapeutic approaches are needed to overcome clinical resistance and improve long-term survival.
Signaling through growth factor receptor tyrosine kinase pathways is important for tumor growth and progression. Receptor engagement can lead to activation of downstream signal transduction cascades involved in cell proliferation and survival, typically including the mitogenactivated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)-Akt pathways.
Aberrant activation of receptor tyrosine kinases, including the insulin-like growth factor 1 receptor (IGF-1R), has been implicated in development and growth of many types of cancer.
Thus, these receptors have become a particularly attractive set of drug targets (3) .
Several lines of evidence suggest that IGF-1R signaling in particular contributes to malignant transformation and cancer growth and survival. Overexpression of IGF-1R in murine and human fibroblasts promotes oncogenic transformation (4) . IGF-1R is required for SV40 large tumor antigen transformation of mouse embryonic fibroblasts (5) . Elevated IGF ligand levels have been detected in patient samples from many tumor types (6) . High IGF ligand levels have been implicated in the promotion of tumor growth in several mouse models of cancer and 4 lead to increased risk for prostate, breast, and lung cancers (7) (8) (9) . It has also been shown that IGF-1R upregulation can lead to chemotherapeutic resistance (10) . types. It has also been shown to inhibit growth of several tumor types in vivo (11) . Currently OSI-906 is being evaluated clinically in patients with many cancer types, including colorectal, ovarian, and lung cancer (12) .
With regard to SCLC, IGF-1R has been reported to be highly expressed in both cell lines and patient tumors (13) (14) (15) (16) (17) . Signaling through the IGF-1R pathway has been implicated in the development and growth of SCLC (14, 18, 19) . Several reports have suggested that IGF-1R inhibitors, including both monoclonal antibodies and RTK inhibitors, can limit growth and induce apoptosis in SCLC cell lines (20) (21) (22) 
Materials and Methods
Cell Lines. The following cell lines were authenticated by short tandem repeat (STR) analysis using the StemElite ID System (Promega): H69, H82, H146, H187, H209, H345, H446, H510A, H526, H720, H774, H1092, and H1930. All cell lines were grown and maintained in conditions recommended by American Type Culture Collection.
MTS Cell Proliferation Assays. Cells were plated in quadruplicate and treated with OSI-906 for 72 hours at doses ranging from 10 nM to 10 µM. MTS cell proliferation assays were performed following manufacturer instructions using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). IC 50 values were extrapolated from dose response curves using the GraphPad Prism program. OSI-906 sensitivity was defined as an IC 50 less than 1 µM.
This threshold was functionally defined based on an estimate of maximal predicted tumor drug levels achievable in vivo: OSI-906 plasma C max after a 50 mg/kg oral dose in mice (as used in our xenograft experiments, see below) is 2.68 µM (11) .
Western Blots. Protein was isolated from cell pellets and tumor tissue using RIPA buffer with protease and phosphatase inhibitor cocktails (Sigma) and run on 10 or 12% Bis-Tris gels with MOPS running buffer (Invitrogen). Membranes were probed with antibodies for phospho-IGF-1Rβ (Y1135/6)/IRβ (Y1150/1), phospho-Akt (S473), phospho-ERK (T202/Y204), phospho-P70S6K, IR, AKT, ERK (Cell Signaling), IGF-1Rβ, GAPDH, and β-Actin (Santa Cruz) following manufacturer instructions. Relative protein levels were measured using the BioRad Quantity One software and calculated by normalizing to control (either GAPDH or β-Actin).
Differences between the sensitive and resistant groups were analyzed using the Wilcoxon rank sum test.
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RT-PCR. RNA was isolated from cells using the Qiagen RNeasy Mini kit and reverse transcribed using Qiagen Quantitect Reverse Transcription kit. PCR was performed using conditions and primers specific for IGF-1, IGF-2 (23), IGFBP3 (24) , IGFBP6 (25) , and GAPDH (26) as previously reported. Products were analyzed on 1.5% agarose gels.
Cell Viability Assays and MEK inhibitors. Cells were plated in quadruplicate and treated with OSI-906 and/or AZD6244 for 72 hours at doses indicated. Cell viability was measured using a CellTiter-Glo® Luminescent Cell Viability Assay (Promega) on a compatible luminometer plate reader. The MEK inhibitors U0126 (#S1102), GSK1120212 (#S2673) and AZD6244 (#S1008) were purchased from Selleck Chemicals.
Overexpression of a constitutively active MEK mutant. Gateway cloning was used to introduce a constitutively active MEK mutant (MEKDD) into the destination plasmid pLenti6/V5-DEST (Life Technologies). The plasmid pDONR223-MEKDD was obtained from Dr. David Root through Addgene (Addgene plasmid #31202) and was generated as previously described (27) . Lentiviral particles were generated using a three-plasmid system and infected as per the RNAi Consortium Library Production and Performance Protocols, Broad Institute (28).
Twenty-four hours after infection, NCI-H187 cells were maintained in media containing blasticidin. Protein was isolated and screened for phospho-ERK expression as described above.
Cells were treated with several doses of OSI-906 and assayed by the MTS Cell Proliferation assay in order to determine IC 50 values as described above. 
Results
We analyzed 19 SCLC cell lines, including three cell lines derived from primary patient tumors, for sensitivity to OSI-906. Cell lines were plated in quadruplicate and treated with doses of OSI-906 ranging from 10 nM to 10 µM for 72 hrs. MTS assays were performed and IC 50 values were extrapolated from dose response curves (Table 1) 
any lines tested, sensitive or resistant, and in fact may be slightly antagonistic (Supplemental Figure 3B & C) . Further, the expression of a constitutively-active mutant form of MEK in one of the most OSI-906-sensitive cell lines, H187, did not confer therapeutic resistance to OSI-906 (Supplemental Figure 3D) . Therefore, while it appears that high baseline levels of phospho-ERK may correlate with relative intrinsic resistance to OSI-906, ERK phosphorylation alone does not affect resistance, arguing against combination treatment approaches with MEK inhibitors as a therapeutic approach to overcome OSI-906 resistance. expression correlates with sensitivity to IGF-1R inhibition may vary by cancer type, and by type of IGF-1R inhibitor. Going further, we also measured the expression levels of IGF binding proteins, IGFBP3 and IGFBP6 since prior data suggested an association between higher expression levels of these and resistance to IGF-1R inhibition (40) . Again, in our panel of SCLC cell lines, we observed no evident correlation between expression of genes encoding either of these binding proteins and sensitivity to OSI-906.
We also tested whether activation of downstream signaling through phospho-Akt and phospho-ERK had any correlation with OSI-906 sensitivity. While no relationship was seen with phospho-Akt, we were able to define a statistically significant difference between sensitivity and resistance to OSI-906 with regard to phospho-ERK levels. OSI-906 resistant cell lines expressed significantly higher levels of phospho-ERK than sensitive cell lines. This novel observation is supported by data from a microarray study of OSI-906 sensitivity in colorectal cancer cell lines revealing frequent upregulation of MAPK pathway activity in resistant lines (42) .
We assessed the changes in key signaling pathways in response to OSI-906 in both sensitive and resistant cell lines. In both sensitive and resistant cell lines, we were able to Our in vivo analysis of OSI-906 included, for the first time, assessment of activity against primary xenograft tumors. We believe there are advantages to testing therapies for SCLC using the preclinical model of primary patient-derived xenografts as a predictor of ultimate clinical utility (43, 44) . Notably, efficacy in these models in response to another novel therapeutic, a Bcl-2 inhibitor, was more consistent with the observed clinical activity in SCLC than responses obtained using traditional cell line xenografts (45) (46) (47) . The xenograft data presented here support that OSI-906 has significant anti-cancer activity against SCLC tumors in vivo. The detailed in vitro analyses define a subset of SCLC that may be particularly responsive to this agent, and a larger cohort in which this strategy would be predicted to have minimal activity.
These data justify the exploration of IGF-1R inhibition in SCLC in the clinical setting, and the potential biomarkers defined here will need to be validated in that context. Analysis of relative phospho-ERK levels in pretreatment tumor biopsies of patients enrolling on these studies would be of interest, and may help focus phase II studies of OSI-906 and other IGF-1R inhibitors. Data presented herein would suggest that tumors demonstrating increased levels of phospho-ERK would be relatively resistant to this type of therapy. 
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